Izalontamab Brengitecan

4 trials 3 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

0 Completed trials

1 Sponsors

15 Countries

Phase II/III

Phase I/II

Phase II/III: 3 Phase I/II: 1

Indications tested

Non-small cell lung cancer 1

Sponsors using this IMP

Bristol-Myers Squibb Services Unlimited Company 4

All trials

4 total

IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 Phase II/III 10 countries Bristol-Myers Squibb Services Unlimited Company
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af… Recruiting

2025-522400-24-00 Phase II/III 11 countries Bristol-Myers Squibb Services Unlimited Company
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Phase II/III 10 countries Bristol-Myers Squibb Services Unlimited Company
A Phase 1/2a Study of BMS-986507 (BL-B01D1) in Adult Participants with Advanced Solid Tumors Recruiting

2024-514947-27-00 Phase I/II 4 countries Bristol-Myers Squibb Services Unlimited Company

Showing 1–4 of 4 trials

← All drugs A–Z